Antagonism of microRNA-126 suppresses the effector function of T H2 cells and the development of allergic airways disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 44, 2009, Pages 18704-18709

  Mattes, Joerg ^a   Collison, Adam ^a   Plank, Maximilian ^a   Phipps, Simon ^a   Foster, Paul S ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Animal model; Asthma; Inflammation; microRNA; TH2 cytokines

Indexed keywords

MICRORNA; MICRORNA 126; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; EOSINOPHIL; GENE EXPRESSION; HOUSE DUST; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH2 CELL;

ANIMALS; ANTIGENS, DERMATOPHAGOIDES; BRONCHIAL HYPERREACTIVITY; GENE EXPRESSION REGULATION; GENE SILENCING; INFLAMMATION; LUNG; MICE; MICE, INBRED BALB C; MICRORNAS; MYELOID DIFFERENTIATION FACTOR 88; RESPIRATORY HYPERSENSITIVITY; TH2 CELLS; TOLL-LIKE RECEPTOR 4;

ANIMALIA; PYROGLYPHIDAE;

EID: 70549095099     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0905063106     Document Type: Article

References (44)

1. Bochner BS, Undem BJ, Lichtenstein LM (1994) Immunological aspects of allergic asthma. Annu Rev Immunol 12:295-335.
2. Eder W, Ege MJ, von Mutius E (2006) The asthma epidemic. N Engl J Med 355:2226-2235.
3. Wills-Karp M (1999) Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 17:255-281.
4. Robinson D, et al. (1993) Activation of CD4+T cells, increased TH2-type cytokinemRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 92:313-324.
5. Eisenbarth SC, et al. (2002) Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 196:1645-1651.
6. Eisenbarth SC, Cassel S, Bottomly K (2004) Understanding asthma pathogenesis: Linking innate and adaptive immunity. Curr Opin Pediatr 16:659-666.
7. Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol 1:135-145.
8. Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2:675-680.
9. Poltorak A, et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282:2085-2088.
10. Taylor MJ, Cross HF, Bilo K (2000) Inflammatory responses induced by the filarial nematode Brugia malayi are mediated by lipopolysaccharide-like activity from endosymbiotic Wolbachia bacteria. J Exp Med 191:1429-1436.
11. Michel O, et al. (1996) Severity of asthma is related to endotoxin in house dust. Am J Respir Crit Care Med 154:1641-1646.
12. Alexis N, Eldridge M, Reed W, Bromberg P, Peden DB (2001) CD14-dependent airway neutrophil response to inhaled LPS: Role of atopy. J Allergy Clin Immunol 107:31-35.
13. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD (2008) MicroRNAs: New regulators of immune cell development and function. Nat Immunol 9:839-845.
14. Bartel DP (2009) microRNAs: Target recognition and regulatory functions. Cell 136:215-233.
15. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D (2007) microRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 104:1604-1609.
16. Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103:12481-12486.
17. LindsayMA(2008) microRNAs and the immune response. Trends Immunol 29:343-351.
18. Xiao C, RajewskyK(2009) microRNA control in theimmunesystem: Basic principles. Cell 136:26-36.
19. Krutzfeldt J, et al. (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438:685-689.
20. Calin GA, et al. (2005)AmicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353:1793-1801.
21. Rodriguez A, et al. (2007) Requirement of bic/microRNA-155 for normal immune function. Science 316:608-611.
22. Care A, et al. (2007) MicroRNA-133 controls cardiac hypertrophy. Nat Med 13:613-618.
23. Mattes J, Collison A, Foster PS (2008) Emerging role of microRNAs in disease pathogenesis and strategies for therapeutic modulation. Curr Opin Mol Ther 10:150-157.
24. Cates EC, et al. (2004) Intranasal exposure of mice to house dust mite elicits allergic airway inflammation via a GM-CSF-mediated mechanism. J Immunol 173:6384-6392.
25. Herbert C, et al. (2008) Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma. Clin Exp Allergy 38:847-856.
26. Gavett SH, Chen X, Finkelman F, Wills-Karp M (1994) Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am J Respir Cell Mol Biol 10:587-593.
27. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG (1996) Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 183:195-201.
28. Mattes J, et al. (2002) Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med 195:1433-1444.
29. Wills-Karp M, et al. (1998) Interleukin-13: Central mediator of allergic asthma [see comments]. Science 282:2258-2261.
30. Grunig G, et al. (1998) Requirement for IL-13 independently of IL-4 in experimental asthma [see comments]. Science 282:2261-2263.
31. Lichtinger M, Ingram R, Hornef M, Bonifer C, Rehli M (2007) Transcription factor PU.1 controls transcription start site positioning and alternative TLR4 promoter usage. J Biol Chem 282:26874-26883.
32. Brunner C, et al. (2007) BOB.1/OBF.1 controls the balance of TH1 and TH2 immune responses. EMBO J 26:3191-3202.
33. Asirvatham AJ, Gregorie CJ, Hu Z, Magner WJ, Tomasi TB (2008) microRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components. Mol Immunol 45:1995-2006.
34. Mattes J, Yang M, Foster PS (2007) Regulation of microRNA by antagomirs: A new class of pharmacological antagonists for the specific regulation of gene function? Am J Respir cell Mol Biol 36:8-12.
35. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D (2009) Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA 106:7113-7118.
36. Vigorito E, et al. (2007) microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 27:847-859.
37. Bazzoni F, et al. (2009) Induction and regulatory function of miR-9 inhumanmonocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci USA 106:5282-5287.
38. Ceppi M, et al. (2009) MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci USA 106:2735-2740.
39. Lambrecht BN, et al. (2000) Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest 106:551-559.
40. van Rijt LS, et al. (2005) In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. J Exp Med 201:981-991.
41. Weckmann M, et al. (2007) Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease. Nat Med 13:1308-1315.
42. Luo Y, Fujii H, Gerster T, Roeder RG (1992) A novel B cell-derived coactivator potentiates the activation of immunoglobulin promoters by octamer-binding transcription factors. Cell 71:231-241.
43. Schubart DB, Rolink A, Kosco-Vilbois MH, Botteri F, Matthias P (1996) B-cell-specific coactivator OBF-1/OCA-B/Bob1 required for immune response and germinal centre formation. Nature 383:538-542.
44. Kumar RK, et al. (2002) Eotaxin expression by epithelial cells and plasma cells in chronic asthma. Lab Invest 82:495-504.